Breakthrough in relapsed multiple myeloma with PANORAMA 1 study

Breakthrough in relapsed multiple myeloma with PANORAMA 1 study

EMJ

6 years
2,610 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Speaking to EMJ from the 19th Congress of the European Hematology Association (EHA 19) meeting, Prof. Paul Richardson , Dana-Farber Cancer Institute, USA, discusses results seen from the breakthrough PANORAMA1 study, a global randomised, double-blind, placebo-controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. He outlines the primary end-point results and side effects observed, and comments on the clinical meaningfulness of these HDAC trial results. Results of sub-sets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma. Keywords: EMJ Relapsed Multiple Myeloma PANORAMA 1 European Hematology Association (EHA19) Prof. Paul Richardson Dana-Farber Cancer Institute Panobinostat Bortezomib Dexamethasone HDAC Ricolinostat (ACY-1215)
Up Next Autoplay